Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hib-DTaP vaccine - GlaxoSmithKline

Drug Profile

Hib-DTaP vaccine - GlaxoSmithKline

Alternative Names: Hib-DTP-acellular vaccine - GlaxoSmithKline; Infanrix-Hib

Latest Information Update: 22 Jan 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Pertussis; Tetanus

Most Recent Events

  • 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 06 Apr 2000 Launched for Diphtheria in United Kingdom (IM)
  • 06 Apr 2000 Launched for Haemophilus infections in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top